14th Alzheimer's and Parkinson's Drug Development Summit

Memo

The approval of the first anti-amyloid drugs has resurrected the neurodegenerative disease space, opening the door for enhanced competition and innovation to develop novel disease-modifying therapies. However, as challenges remain in the clinical adoption of Lecanemab and Donanemab, the field needs to navigate the move towards disease-modifying therapeutics. Capitalizing on the surge of innovation across new targets, lessons learned from clinical setbacks, groundbreaking progress in blood-based diagnostics, and more, the 14th Alzheimer’s and Parkinson’s Drug Development Summit returns as the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical and regulatory. URLs:Tickets: https://go.evvnt.com/3259347-2?pid=5569 Brochure: https://go.evvnt.com/3259347-3?pid=5569  Date and Time: Tue, 03 Feb 2026 08:00 - Thu, 05 Feb 2026 17:00 Venue details: Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, Massachusetts, 02128, United States Prices:Drug Developer Pricing - Conference + Pre-Conference Day: USD 3497.00,Drug Developer Pricing - Conference Only: USD 2599.00,Academic Pricing - Conference + Pre-Conference Day: USD 2897.00,Academic Pricing - Conference Only: USD 2199.00,Solution Provider Pricing - Conference + Pre-Conference Day: USD 5197.00,Solution Provider Pricing - Conference Only: USD 3799.00 Speakers: Ross Jeggo, Head of Neurology Research, Biogen, Jessica Wu, Scientific Director, Biogen, Achim Kless PhD, Senior Director, Discovery Neuroscience Research, Neuroscience Genetics, Eli Lilly and Co., Dimitry Ofengeim, Senior Scientist, Head, of Distinguished, Neuroinflammation and Precision Neurology Group, Sanofi, Gennaro Pagano, Group Leader and Expert Medical Director In Early Development, Roche, Nellwyn Hagan, Scientific Director Neurodegenerative Disorders, Takeda Pharmaceutical, Gyan Srivastava, Associate Director and Head Of Computational Biology, Alexion Pharma UK, Malleswari Challagundla, Senior Scientist II, Abbvie, Laura Cohen, Vice President, Alzheimer's Environment Shaping, Eli Lilly and Co., Abigail Mariga, Senior Principal Scientist, Bristol Myers Squibb, Nima Shariati, Project Statistician and Data Science Team Lead, Roche, Danielle Graham, Vice President and Head of Biomarkers, Biogen, Roman Loonis, Associate Medical Director, Clinical Sciences, Neurodegenerative Disorders, Takeda Pharmaceutical, Eric Siemers, Chief Medical Officer, Acumen Pharmaceuticals, Kira Holmström, Head of Biomarker Research, Herantis, Bruce Morimoto, Head, Drug Development, Fuku Biotech, Lili Zhang, Senior Vice President, Head of Preclinical Development, Aprinoia Therapeutics Inc., Paul Gregor, Chief Executive Officer, Gismo Therapeutics Inc., Raj Rajagovindan, Vice President - Translational Medicine, Voyager Therapeutics, Inc, Paul Ashton, President and Chief Executive Officer, Inflammasome Therapeutics, Susan Abushakra, Chief Medical Officer, Alzheon, Jennifer Johnston, Co-Founder and Chief Executive Officer, NysnoBio, Marianthi Papakosta, Director, Neuroscience Research, Neurocrine Biosciences, Patrick Kesslak, Senior Research Fellow, Alzheon, Sathya Ganesan, Director, Global Regulatory Affairs, UCB, Yongchang Qiu, Founder and Chief Executive Officer, Lysoway Therapeutics, Karen Quadrini, Director, Clinical Biomarkers, Prothena Corporation, Malú Tansey, Director of Neuroimmunology Research and Executive Associate Director of Education Stark Neuroscience Research Institute, Indiana University School of Medicine, Alexander Shtilbans, Director of Movement Disorder Program, HSS, Hospital for Special Surgery; Assistant Professor of Neurology, Cornell University, Pardeep Pabla, Living with Parkinson's Disease, Tharick A Pascoal, Assistant Professor, UPitt, Mira Chaurushiya, Managing Director, Westlake Village BioPartners, Manik Kuchroo, Investor, Polaris Partners Ltd, Brendan Hussey, Vice President, JLS Fund, Fernanda Cerqueira, Senior Associate Director - Research Programs and Translational, The Michael J. Fox Foundation for Parkinson's Research